- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Submit Immunogenicity Data: CDSCO Panel Tells Pfizer on Pneumococcal Polysaccharide Conjugate Vaccine study
New Delhi: Reviewing the Phase III clinical trial report of the 20 valent Pneumococcal Conjugate Vaccine (20vPnC) presented by Pfizer, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has opined the firm submit the global immunogenicity data of all subjects vis-Ã -vis the immunogenicity data of Indian subjects and the immunogenicity data of Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed) I.P., 13 valent of Indian subjects.
This came after Pfizer presented the Phase III clinical trial report of the 20-valent pneumococcal conjugate vaccine (20vPnC) of a study titled " A Phase III, single-arm, multicenter trial to describe the safety and immunogenicity of a 20 valent Pneumococcal Conjugate Vaccine in Pneumococcal vaccine-naïve adults ≥18 years of age in India’’.
Pneumococcal 20-valent conjugate vaccine is an active immunizing agent used to prevent infection caused by certain types of pneumococcal bacteria (Streptococcus pneumoniae). It works by causing the body to produce its protection (antibodies) against the disease.
At the recent SEC meeting for Vaccine held on July 31, 2024, the expert panel reviewed the Phase III clinical trial report of 20 valent Pneumococcal Conjugate Vaccine (20vPnC) of study titled " A Phase III, single-arm, multicenter trial to describe the safety and immunogenicity of a 20 valent Pneumococcal Conjugate Vaccine in Pneumococcal vaccine-naïve adults ≥18 years of age in India’’.
After detailed deliberation, the committee recommended that the firm should submit the global immunogenicity data of all subjects vis-Ã -vis the immunogenicity data of Indian subjects and the immunogenicity data of Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed) I.P., 13 valent of Indian subjects for further deliberation.
Also Read:CDSCO Panel Approves IQVIA RDS's Protocol Amendment Proposal for Spesolimab study
Doctor of Pharmacy
Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751